secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001193125-24-050724
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atea reports $136M FY2023 net loss; HCV Phase 2 confirms 98% SVR4; COVID-19 Phase 3 enrollment >1,400
--------------------------------------------------------------------------------

- Q4 net loss $39.2M ($0.47 diluted EPS) vs $34.4M loss in Q4 2022; FY net loss $136.0M ($1.63) vs $115.9M.
- Cash & marketable securities $578.1M at Dec 31, 2023, down from $646.7M at Dec 31, 2022.
- HCV Phase 2 lead-in final results: 98% SVR4 (58/59 patients); enrollment reinitiated for up to 220 patients, including cirrhotics.
- COVID-19 Phase 3 SUNRISE-3: >1,400 patients enrolled in monotherapy cohort; interim analyses expected March 2024 and Q2 2024.
- Topline results for SUNRISE-3 and HCV Phase 2 SVR12 both anticipated in H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312524050724/0001193125-24-050724-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312524050724/d791287d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-050724

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer